NO324471B1 - Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav og farmasoytisk sammensetning - Google Patents

Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav og farmasoytisk sammensetning Download PDF

Info

Publication number: NO324471B1
Authority: NO; Norway
Prior art keywords: hydroxy; methoxyquinazoline; propoxy; fluorophenylamino; chloro
Prior art date: 2000-04-07

Application number

NO20024763A

Other languages

English (en)

Norwegian (no)

Other versions

NO20024763L (no

NO20024763D0 (no

Inventor

Elaine Sophie Elizabeth Stokes

Laurent Francois And Hennequin

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2002-10-03

Publication date

2007-10-29

2002-10-03 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2002-10-03 Publication of NO20024763D0 publication Critical patent/NO20024763D0/no

2002-11-19 Publication of NO20024763L publication Critical patent/NO20024763L/no

2007-10-29 Publication of NO324471B1 publication Critical patent/NO324471B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 56
238000002360 preparation method Methods 0.000 title claims abstract description 11
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
230000008569 process Effects 0.000 title claims abstract description 4
125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title abstract description 6
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 31
229920006395 saturated elastomer Polymers 0.000 claims abstract description 27
229910052760 oxygen Inorganic materials 0.000 claims abstract description 23
229910052717 sulfur Inorganic materials 0.000 claims abstract description 21
125000005842 heteroatom Chemical group 0.000 claims abstract description 19
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
230000001772 anti-angiogenic effect Effects 0.000 claims abstract description 7
241001465754 Metazoa Species 0.000 claims abstract description 6
125000002373 5 membered heterocyclic group Chemical group 0.000 claims abstract description 3
125000004070 6 membered heterocyclic group Chemical group 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 201
-1 cyano, amino Chemical group 0.000 claims description 89
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 73
150000003839 salts Chemical class 0.000 claims description 73
125000001424 substituent group Chemical group 0.000 claims description 67
229910052736 halogen Inorganic materials 0.000 claims description 63
150000002367 halogens Chemical class 0.000 claims description 63
125000000217 alkyl group Chemical group 0.000 claims description 53
125000000623 heterocyclic group Chemical group 0.000 claims description 39
229910052739 hydrogen Inorganic materials 0.000 claims description 37
239000001257 hydrogen Substances 0.000 claims description 37
238000006243 chemical reaction Methods 0.000 claims description 36
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
125000002947 alkylene group Chemical group 0.000 claims description 22
150000002431 hydrogen Chemical class 0.000 claims description 21
125000003545 alkoxy group Chemical group 0.000 claims description 19
230000000694 effects Effects 0.000 claims description 19
229910052799 carbon Inorganic materials 0.000 claims description 18
125000006239 protecting group Chemical group 0.000 claims description 18
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
125000004419 alkynylene group Chemical group 0.000 claims description 15
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 15
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
125000004450 alkenylene group Chemical group 0.000 claims description 14
125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 13
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
125000004043 oxo group Chemical group O=* 0.000 claims description 12
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 12
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 11
125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 11
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
125000004093 cyano group Chemical group *C#N 0.000 claims description 11
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 10
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
238000010511 deprotection reaction Methods 0.000 claims description 9
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 7
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 7
150000001412 amines Chemical class 0.000 claims description 6
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 5
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 5
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
OPKOKAMJFNKNAS-UHFFFAOYSA-N 2-methylamino-ethanol Natural products CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 claims description 5
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 5
125000004423 acyloxy group Chemical group 0.000 claims description 5
125000003342 alkenyl group Chemical group 0.000 claims description 5
125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 5
125000004414 alkyl thio group Chemical group 0.000 claims description 5
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 5
125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims description 4
241000282414 Homo sapiens Species 0.000 claims description 4
IZKQATIXKMSZMA-UHFFFAOYSA-N [1-[2-(4-chloro-2-fluoro-5-hydroxyanilino)-6-methoxyquinazolin-7-yl]oxy-3-pyrrolidin-1-ylpropan-2-yl] acetate Chemical compound N1=C2C=C(OCC(CN3CCCC3)OC(C)=O)C(OC)=CC2=CN=C1NC1=CC(O)=C(Cl)C=C1F IZKQATIXKMSZMA-UHFFFAOYSA-N 0.000 claims description 4
125000000304 alkynyl group Chemical group 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 4
GREVZXMSYNOZCD-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[methyl(propan-2-yl)amino]propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN(C)C(C)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F GREVZXMSYNOZCD-UHFFFAOYSA-N 0.000 claims description 3
230000002137 anti-vascular effect Effects 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
125000004434 sulfur atom Chemical group 0.000 claims description 3
125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 2
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
AITBBSQVMJDSCF-UHFFFAOYSA-N 1-[3-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-2-hydroxypropyl]pyrrolidin-3-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CC(O)CC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F AITBBSQVMJDSCF-UHFFFAOYSA-N 0.000 claims description 2
JFCQRFBWDHFYKX-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(3,6-dihydro-2h-pyridin-1-yl)propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CC=CCC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F JFCQRFBWDHFYKX-UHFFFAOYSA-N 0.000 claims description 2
ODYHIBVHUIEHFT-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[4-(2-hydroxyethyl)piperazin-1-yl]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCN(CCO)CC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F ODYHIBVHUIEHFT-UHFFFAOYSA-N 0.000 claims description 2
DZJULENXWVUIJM-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[4-(3-hydroxypropyl)piperazin-1-yl]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCN(CCCO)CC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F DZJULENXWVUIJM-UHFFFAOYSA-N 0.000 claims description 2
IDYZXRHNDUCKIA-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[tert-butyl(methyl)amino]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN(C)C(C)(C)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F IDYZXRHNDUCKIA-UHFFFAOYSA-N 0.000 claims description 2
HMOWYVHFBHYIFM-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-pyrrolidin-1-ylpropan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCCC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F HMOWYVHFBHYIFM-UHFFFAOYSA-N 0.000 claims description 2
JKLLTOCYSUUYIR-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(2,5-dihydropyrrol-1-yl)propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CC=CC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F JKLLTOCYSUUYIR-UHFFFAOYSA-N 0.000 claims description 2
BVTDRPZUSZUJCV-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(2,5-dimethyl-2,5-dihydropyrrol-1-yl)propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3C(C=CC3C)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F BVTDRPZUSZUJCV-UHFFFAOYSA-N 0.000 claims description 2
YDPMBFIPVUYLIG-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(2-methylpyrrolidin-1-yl)propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3C(CCC3)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F YDPMBFIPVUYLIG-UHFFFAOYSA-N 0.000 claims description 2
NDUSBIUVSGDDLE-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(4-methylpiperidin-1-yl)propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCC(C)CC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F NDUSBIUVSGDDLE-UHFFFAOYSA-N 0.000 claims description 2
KIIHJUUYOQYLQI-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCN(CCN4CCOCC4)CC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F KIIHJUUYOQYLQI-UHFFFAOYSA-N 0.000 claims description 2
SJADPSGCLSZPOL-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-morpholin-4-ylpropan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCOCC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F SJADPSGCLSZPOL-UHFFFAOYSA-N 0.000 claims description 2
QIHIMPROVJYEAQ-UHFFFAOYSA-N 3-[[3-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-2-hydroxypropyl]-methylamino]propanenitrile Chemical compound N1=CN=C2C=C(OCC(O)CN(C)CCC#N)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F QIHIMPROVJYEAQ-UHFFFAOYSA-N 0.000 claims description 2
125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
125000002837 carbocyclic group Chemical group 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 2
125000006413 ring segment Chemical group 0.000 claims description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
WLOHPRTXMLRWDG-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[methyl(2-methylpropyl)amino]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN(C)CC(C)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F WLOHPRTXMLRWDG-UHFFFAOYSA-N 0.000 claims 1
FMOIUGNZRHTOFZ-UHFFFAOYSA-N ClC1=CC(=C(C=C1)NC1=NC=NC2=CC(=C(C=C12)OC)OCC(CN1CCCCCC1)O)F.ClC1=CC(=C(C=C1)NC1=NC=NC2=CC(=C(C=C12)OC)OCC(CN1CCCCC1)O)F Chemical compound ClC1=CC(=C(C=C1)NC1=NC=NC2=CC(=C(C=C12)OC)OCC(CN1CCCCCC1)O)F.ClC1=CC(=C(C=C1)NC1=NC=NC2=CC(=C(C=C12)OC)OCC(CN1CCCCC1)O)F FMOIUGNZRHTOFZ-UHFFFAOYSA-N 0.000 claims 1
LXTGQZYQHVMJOU-UHFFFAOYSA-N ClC1=CC(=C(C=C1O)NC1=NC2=CC(=C(C=C2C=N1)OC)OCC(CN1CCCCC1)OC(C)=O)F.ClC1=CC(=C(C=C1O)NC1=NC2=CC(=C(C=C2C=N1)OC)OCC(CN1CCCC1)O)F Chemical compound ClC1=CC(=C(C=C1O)NC1=NC2=CC(=C(C=C2C=N1)OC)OCC(CN1CCCCC1)OC(C)=O)F.ClC1=CC(=C(C=C1O)NC1=NC2=CC(=C(C=C2C=N1)OC)OCC(CN1CCCC1)O)F LXTGQZYQHVMJOU-UHFFFAOYSA-N 0.000 claims 1
125000005236 alkanoylamino group Chemical group 0.000 claims 1
125000001589 carboacyl group Chemical group 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 17
238000011282 treatment Methods 0.000 abstract description 14
201000011510 cancer Diseases 0.000 abstract description 7
201000010099 disease Diseases 0.000 abstract description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
230000008728 vascular permeability Effects 0.000 abstract description 6
125000003118 aryl group Chemical group 0.000 abstract description 4
206010039073 rheumatoid arthritis Diseases 0.000 abstract description 4
230000001603 reducing effect Effects 0.000 abstract 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 81
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 56
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
239000000203 mixture Substances 0.000 description 30
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
239000000243 solution Substances 0.000 description 26
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 25
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
AOBYGTALIHMYNT-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(oxiran-2-ylmethoxy)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCC3OC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F AOBYGTALIHMYNT-UHFFFAOYSA-N 0.000 description 24
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
YYPBSYUXHHLGJQ-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-6-methoxy-7-(oxiran-2-ylmethoxy)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCC3OC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F YYPBSYUXHHLGJQ-UHFFFAOYSA-N 0.000 description 17
239000002585 base Substances 0.000 description 16
239000000047 product Substances 0.000 description 16
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 15
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
239000007787 solid Substances 0.000 description 15
239000002904 solvent Substances 0.000 description 15
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 13
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
238000001914 filtration Methods 0.000 description 12
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
239000002244 precipitate Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 12
229910021529 ammonia Inorganic materials 0.000 description 11
238000003556 assay Methods 0.000 description 11
239000003039 volatile agent Substances 0.000 description 11
NARVIWMVBMUEOG-UHFFFAOYSA-N 2-Hydroxy-propylene Natural products CC(O)=C NARVIWMVBMUEOG-UHFFFAOYSA-N 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 10
108090000790 Enzymes Proteins 0.000 description 10
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
229940088598 enzyme Drugs 0.000 description 10
238000007363 ring formation reaction Methods 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000003085 diluting agent Substances 0.000 description 9
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
239000012442 inert solvent Substances 0.000 description 9
239000007858 starting material Substances 0.000 description 9
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 8
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
229960001701 chloroform Drugs 0.000 description 8
238000001816 cooling Methods 0.000 description 8
238000001704 evaporation Methods 0.000 description 8
230000008020 evaporation Effects 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000001819 mass spectrum Methods 0.000 description 7
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 6
UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
229910000027 potassium carbonate Inorganic materials 0.000 description 6
108091008598 receptor tyrosine kinases Proteins 0.000 description 6
102000027426 receptor tyrosine kinases Human genes 0.000 description 6
239000000377 silicon dioxide Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
DEIBXAPEZDJDRC-UHFFFAOYSA-M (dimethylaminomethylideneamino)methylidene-dimethylazanium;chloride Chemical compound [Cl-].CN(C)C=NC=[N+](C)C DEIBXAPEZDJDRC-UHFFFAOYSA-M 0.000 description 5
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 5
102000001301 EGF receptor Human genes 0.000 description 5
108060006698 EGF receptor Proteins 0.000 description 5
239000012267 brine Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
229910000041 hydrogen chloride Inorganic materials 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
239000010410 layer Substances 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000010992 reflux Methods 0.000 description 5
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
241000701447 unidentified baculovirus Species 0.000 description 5
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 4
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
108091008605 VEGF receptors Proteins 0.000 description 4
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
229960001456 adenosine triphosphate Drugs 0.000 description 4
125000004848 alkoxyethyl group Chemical group 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
150000001721 carbon Chemical group 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 4
239000003701 inert diluent Substances 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
229930182817 methionine Natural products 0.000 description 4
XHFGWHUWQXTGAT-UHFFFAOYSA-N n-methylpropan-2-amine Chemical compound CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
238000003756 stirring Methods 0.000 description 4
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 4
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108091008794 FGF receptors Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
HETCEOQFVDFGSY-UHFFFAOYSA-N Isopropenyl acetate Chemical group CC(=C)OC(C)=O HETCEOQFVDFGSY-UHFFFAOYSA-N 0.000 description 3
208000007766 Kaposi sarcoma Diseases 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
VWVSXQLIXAGWLT-UHFFFAOYSA-N [1-(4-chloro-2-fluoro-6-methoxyquinazolin-7-yl)oxy-3-[2-(3-hydroxyanilino)piperidin-1-yl]propan-2-yl] acetate Chemical compound ClC1=NC(=NC2=CC(=C(C=C12)OC)OCC(CN1C(CCCC1)NC1=CC=CC(=C1)O)OC(C)=O)F VWVSXQLIXAGWLT-UHFFFAOYSA-N 0.000 description 3
PWZRIULGMUVXDL-UHFFFAOYSA-N [1-(4-chloro-6-methoxyquinazolin-7-yl)oxy-3-pyrrolidin-1-ylpropan-2-yl] acetate Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCC(OC(C)=O)CN1CCCC1 PWZRIULGMUVXDL-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 3
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
201000011066 hemangioma Diseases 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
150000003246 quinazolines Chemical class 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
150000003852 triazoles Chemical class 0.000 description 3
DTQVDTLACAAQTR-DYCDLGHISA-N trifluoroacetic acid-d1 Chemical compound [2H]OC(=O)C(F)(F)F DTQVDTLACAAQTR-DYCDLGHISA-N 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
230000002792 vascular Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
KWCVUWUJDCWGGM-UHFFFAOYSA-N (6-methoxy-4-oxo-7-phenylmethoxyquinazolin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound COC1=CC(C(N(COC(=O)C(C)(C)C)C=N2)=O)=C2C=C1OCC1=CC=CC=C1 KWCVUWUJDCWGGM-UHFFFAOYSA-N 0.000 description 2
NZXRRNLMXLRCAF-UHFFFAOYSA-N (7-hydroxy-6-methoxy-4-oxoquinazolin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound N1=CN(COC(=O)C(C)(C)C)C(=O)C2=C1C=C(O)C(OC)=C2 NZXRRNLMXLRCAF-UHFFFAOYSA-N 0.000 description 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
QUQUOXVKLYXCSE-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[methyl(2-methylpropyl)amino]propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN(C)CC(C)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F QUQUOXVKLYXCSE-UHFFFAOYSA-N 0.000 description 2
WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 2
RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
LWEOFVINMVZGAS-UHFFFAOYSA-N 3-piperazin-1-ylpropan-1-ol Chemical compound OCCCN1CCNCC1 LWEOFVINMVZGAS-UHFFFAOYSA-N 0.000 description 2
JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 2
SAJZEJMFAWZNCQ-UHFFFAOYSA-N 4-(2-piperazin-1-ylethyl)morpholine Chemical compound C1CNCCN1CCN1CCOCC1 SAJZEJMFAWZNCQ-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
XIHOMGRMQWNHHB-UHFFFAOYSA-N 4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F XIHOMGRMQWNHHB-UHFFFAOYSA-N 0.000 description 2
XGZKSSTZBKFZMF-UHFFFAOYSA-N 4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F XGZKSSTZBKFZMF-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 2
LBGIYCBNJBHZSZ-UHFFFAOYSA-N 4-chloro-6-methoxy-7-phenylmethoxyquinazoline Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCC1=CC=CC=C1 LBGIYCBNJBHZSZ-UHFFFAOYSA-N 0.000 description 2
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
AFZLCOLNTRPSIF-UHFFFAOYSA-N 5-amino-2-chloro-4-fluorophenol Chemical compound NC1=CC(O)=C(Cl)C=C1F AFZLCOLNTRPSIF-UHFFFAOYSA-N 0.000 description 2
ZCUFFSHMOAEEIL-UHFFFAOYSA-N 6-methoxy-7-phenylmethoxy-1h-quinazolin-4-one Chemical compound COC1=CC2=C(O)N=CN=C2C=C1OCC1=CC=CC=C1 ZCUFFSHMOAEEIL-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010051113 Arterial restenosis Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 2
201000009273 Endometriosis Diseases 0.000 description 2
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
229910021380 Manganese Chloride Inorganic materials 0.000 description 2
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
206010027514 Metrorrhagia Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
208000022873 Ocular disease Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
JTTSJGXCJHGXGE-UHFFFAOYSA-N [1-(4-chloro-6-methoxyquinazolin-7-yl)oxy-3-(4-methylpiperazin-1-yl)propan-2-yl] acetate Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCC(OC(C)=O)CN1CCN(C)CC1 JTTSJGXCJHGXGE-UHFFFAOYSA-N 0.000 description 2
FXAJJIIBICTCQG-UHFFFAOYSA-N [1-[(6-methoxy-4-oxo-1h-quinazolin-7-yl)oxy]-3-(4-methylpiperazin-1-yl)propan-2-yl] acetate Chemical compound COC1=CC(C(NC=N2)=O)=C2C=C1OCC(OC(C)=O)CN1CCN(C)CC1 FXAJJIIBICTCQG-UHFFFAOYSA-N 0.000 description 2
HFJNQMDVJOMZBO-UHFFFAOYSA-N [1-[(6-methoxy-4-oxo-1h-quinazolin-7-yl)oxy]-3-pyrrolidin-1-ylpropan-2-yl] acetate Chemical compound COC1=CC(C(NC=N2)=O)=C2C=C1OCC(OC(C)=O)CN1CCCC1 HFJNQMDVJOMZBO-UHFFFAOYSA-N 0.000 description 2
PQAYAKOPFGRAQI-UHFFFAOYSA-N [1-[2-(4-bromo-2-fluoro-5-hydroxyanilino)-6-methoxyquinazolin-7-yl]oxy-3-pyrrolidin-1-ylpropan-2-yl] acetate Chemical compound N1=C2C=C(OCC(CN3CCCC3)OC(C)=O)C(OC)=CC2=CN=C1NC1=CC(O)=C(Br)C=C1F PQAYAKOPFGRAQI-UHFFFAOYSA-N 0.000 description 2
OLCYQBQZBQCAQU-UHFFFAOYSA-N [7-[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-oxoquinazolin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound COC1=CC(C(N(COC(=O)C(C)(C)C)C=N2)=O)=C2C=C1OCC(O)CN1CCN(C)CC1 OLCYQBQZBQCAQU-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
208000038016 acute inflammation Diseases 0.000 description 2
230000006022 acute inflammation Effects 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
244000309464 bull Species 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000000753 cycloalkyl group Chemical group 0.000 description 2
238000013461 design Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
150000002118 epoxides Chemical class 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000005658 halogenation reaction Methods 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
125000004356 hydroxy functional group Chemical group O* 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
239000011565 manganese chloride Substances 0.000 description 2
235000002867 manganese chloride Nutrition 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000002828 nitro derivatives Chemical class 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
239000007981 phosphate-citrate buffer Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
230000037390 scarring Effects 0.000 description 2
SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229960001922 sodium perborate Drugs 0.000 description 2
YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000007306 turnover Effects 0.000 description 2
239000004066 vascular targeting agent Substances 0.000 description 2
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 1
JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
AIWNPQYVDMVMRI-UHFFFAOYSA-N 1-(azepan-1-yl)-3-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxypropan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCCCCC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F AIWNPQYVDMVMRI-UHFFFAOYSA-N 0.000 description 1
ABJQGZHZISJXGQ-UHFFFAOYSA-N 1-(azetidin-1-yl)-3-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxypropan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3CCC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F ABJQGZHZISJXGQ-UHFFFAOYSA-N 0.000 description 1
HTTCNBOKFHSQKB-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(1-methylimidazol-2-yl)sulfanylpropan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CSC=3N(C=CN=3)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F HTTCNBOKFHSQKB-UHFFFAOYSA-N 0.000 description 1
CPLQXYUANREFAE-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(2,5-dihydropyrrol-1-yl)propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3CC=CC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F CPLQXYUANREFAE-UHFFFAOYSA-N 0.000 description 1
XRWQAHBACWXVHO-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(3,6-dihydro-2h-pyridin-1-yl)propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3CC=CCC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F XRWQAHBACWXVHO-UHFFFAOYSA-N 0.000 description 1
JXEIOYFWHCQHQG-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(dimethylamino)propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN(C)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F JXEIOYFWHCQHQG-UHFFFAOYSA-N 0.000 description 1
PYCAYRVAPOHWIZ-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[2-hydroxyethyl(methyl)amino]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN(C)CCO)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F PYCAYRVAPOHWIZ-UHFFFAOYSA-N 0.000 description 1
NENTWVGZSMZYFY-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[4-(2-hydroxyethyl)piperazin-1-yl]propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3CCN(CCO)CC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F NENTWVGZSMZYFY-UHFFFAOYSA-N 0.000 description 1
KZDXKJCVSQHVGP-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCN(CCN4CCOCC4)CC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F KZDXKJCVSQHVGP-UHFFFAOYSA-N 0.000 description 1
NISNGTDZGFHZFN-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3CCN(CCN4CCOCC4)CC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F NISNGTDZGFHZFN-UHFFFAOYSA-N 0.000 description 1
XQXUUDBJZWCIPH-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[methyl(2-methylpropyl)amino]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN(C)CC(C)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F XQXUUDBJZWCIPH-UHFFFAOYSA-N 0.000 description 1
IDSRXVILPFYIMP-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[tert-butyl(methyl)amino]propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN(C)C(C)(C)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F IDSRXVILPFYIMP-UHFFFAOYSA-N 0.000 description 1
NCHXYJFBBBZYTL-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-morpholin-4-ylpropan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCOCC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F NCHXYJFBBBZYTL-UHFFFAOYSA-N 0.000 description 1
PAXQQOIWSSLUHJ-UHFFFAOYSA-N 1-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-piperidin-1-ylpropan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3CCCCC3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F PAXQQOIWSSLUHJ-UHFFFAOYSA-N 0.000 description 1
LYOVSNVQCKALAG-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(2,5-dimethyl-2,5-dihydropyrrol-1-yl)propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3C(C=CC3C)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F LYOVSNVQCKALAG-UHFFFAOYSA-N 0.000 description 1
BMYFTDPPWFORRC-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(2-methylpyrrolidin-1-yl)propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3C(CCC3)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F BMYFTDPPWFORRC-UHFFFAOYSA-N 0.000 description 1
GUVYTMBALZGYHY-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(4-methylpiperidin-1-yl)propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3CCC(C)CC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F GUVYTMBALZGYHY-UHFFFAOYSA-N 0.000 description 1
WZIKERSKUWTVPC-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-(dimethylamino)propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN(C)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F WZIKERSKUWTVPC-UHFFFAOYSA-N 0.000 description 1
DTEARMPMCDIOJJ-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[2-hydroxyethyl(methyl)amino]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN(C)CCO)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F DTEARMPMCDIOJJ-UHFFFAOYSA-N 0.000 description 1
LBDAJEVRKXEPQF-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[2-hydroxyethyl(methyl)amino]propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN(C)CCO)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F LBDAJEVRKXEPQF-UHFFFAOYSA-N 0.000 description 1
ZHGWILCMQKIQBM-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[4-(2-hydroxyethyl)piperazin-1-yl]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCN(CCO)CC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F ZHGWILCMQKIQBM-UHFFFAOYSA-N 0.000 description 1
GINBOWHEUSWGBU-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3CCN(CCN4CCOCC4)CC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F GINBOWHEUSWGBU-UHFFFAOYSA-N 0.000 description 1
UTRVVZYCBPZUBN-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[ethyl(propan-2-yl)amino]propan-2-ol;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OCC(O)CN(CC)C(C)C)=CC2=NC=NC=1NC1=CC=C(Cl)C=C1F UTRVVZYCBPZUBN-UHFFFAOYSA-N 0.000 description 1
YJUKEKWDTQUAIE-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[ethyl(propyl)amino]propan-2-ol;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OCC(O)CN(CC)CCC)=CC2=NC=NC=1NC1=CC=C(Cl)C=C1F YJUKEKWDTQUAIE-UHFFFAOYSA-N 0.000 description 1
KMLYEAMLHVSZQM-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[methyl(prop-2-ynyl)amino]propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN(C)CC#C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F KMLYEAMLHVSZQM-UHFFFAOYSA-N 0.000 description 1
BBDCUXMPMVBHRW-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[methyl(propan-2-yl)amino]propan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN(C)C(C)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F BBDCUXMPMVBHRW-UHFFFAOYSA-N 0.000 description 1
FPGBHOHUUOCEEN-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-[methyl(propan-2-yl)amino]propan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN(C)C(C)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F FPGBHOHUUOCEEN-UHFFFAOYSA-N 0.000 description 1
CRNDYTCTYKLEGW-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-piperidin-1-ylpropan-2-ol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN3CCCCC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F CRNDYTCTYKLEGW-UHFFFAOYSA-N 0.000 description 1
BGXJUCBVBACYKA-UHFFFAOYSA-N 1-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-3-thiomorpholin-4-ylpropan-2-ol Chemical compound N1=CN=C2C=C(OCC(O)CN3CCSCC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F BGXJUCBVBACYKA-UHFFFAOYSA-N 0.000 description 1
FHTDDANQIMVWKZ-UHFFFAOYSA-N 1h-pyridine-4-thione Chemical compound SC1=CC=NC=C1 FHTDDANQIMVWKZ-UHFFFAOYSA-N 0.000 description 1
TXQDHQBSNAJSHQ-UHFFFAOYSA-N 2,5-dimethyl-2,5-dihydro-1h-pyrrole Chemical compound CC1NC(C)C=C1 TXQDHQBSNAJSHQ-UHFFFAOYSA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
DNPHXICYCDCOAR-UHFFFAOYSA-N 2-amino-5-methoxy-4-phenylmethoxybenzamide Chemical compound COC1=CC(C(N)=O)=C(N)C=C1OCC1=CC=CC=C1 DNPHXICYCDCOAR-UHFFFAOYSA-N 0.000 description 1
ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
QDLMURDWBKKQFE-UHFFFAOYSA-N 2-bromo-4-fluoro-5-[[7-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxyquinazolin-2-yl]amino]phenol Chemical compound N1=C2C=C(OCC(O)CN3CCCC3)C(OC)=CC2=CN=C1NC1=CC(O)=C(Br)C=C1F QDLMURDWBKKQFE-UHFFFAOYSA-N 0.000 description 1
IYWOUJUISJMHSM-UHFFFAOYSA-N 2-chloro-4-fluoro-5-[[7-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxyquinazolin-2-yl]amino]phenol Chemical compound N1=C2C=C(OCC(O)CN3CCCC3)C(OC)=CC2=CN=C1NC1=CC(O)=C(Cl)C=C1F IYWOUJUISJMHSM-UHFFFAOYSA-N 0.000 description 1
125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
RGHPCLZJAFCTIK-UHFFFAOYSA-N 2-methylpyrrolidine Chemical compound CC1CCCN1 RGHPCLZJAFCTIK-UHFFFAOYSA-N 0.000 description 1
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
UNIJBMUBHBAUET-UHFFFAOYSA-N 3-(methylamino)propanenitrile Chemical compound CNCCC#N UNIJBMUBHBAUET-UHFFFAOYSA-N 0.000 description 1
JCVHJSCOMMZTNV-UHFFFAOYSA-N 3-[[3-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxy-2-hydroxypropyl]-methylamino]propanenitrile;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC(O)CN(C)CCC#N)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F JCVHJSCOMMZTNV-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
CSFDTBRRIBJILD-UHFFFAOYSA-N 4-chloro-2-fluoroaniline Chemical compound NC1=CC=C(Cl)C=C1F CSFDTBRRIBJILD-UHFFFAOYSA-N 0.000 description 1
UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
MRWRKNRDHHLEPA-UHFFFAOYSA-N 5-amino-2-bromo-4-fluorophenol Chemical compound NC1=CC(O)=C(Br)C=C1F MRWRKNRDHHLEPA-UHFFFAOYSA-N 0.000 description 1
HZUCGIFQFAMADM-UHFFFAOYSA-N 6-methoxyquinazoline Chemical compound N1=CN=CC2=CC(OC)=CC=C21 HZUCGIFQFAMADM-UHFFFAOYSA-N 0.000 description 1
PENSKUBPAQQRLK-UHFFFAOYSA-N 7-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-1h-quinazolin-4-one Chemical compound COC1=CC(C(NC=N2)=O)=C2C=C1OCC(O)CN1CCCC1 PENSKUBPAQQRLK-UHFFFAOYSA-N 0.000 description 1
RUZDBTAZVSDLIM-UHFFFAOYSA-N 7-[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-1h-quinazolin-4-one Chemical compound COC1=CC(C(NC=N2)=O)=C2C=C1OCC(O)CN1CCN(C)CC1 RUZDBTAZVSDLIM-UHFFFAOYSA-N 0.000 description 1
BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
102000012936 Angiostatins Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
YAANEPHQIBZAJM-UHFFFAOYSA-N COC1=CC2=C(NC(C(F)=C3)=CC=C3Cl)N=CN=C2C=C1OCC(C[S+]1CCNCC1)O.Cl Chemical compound COC1=CC2=C(NC(C(F)=C3)=CC=C3Cl)N=CN=C2C=C1OCC(C[S+]1CCNCC1)O.Cl YAANEPHQIBZAJM-UHFFFAOYSA-N 0.000 description 1
AYHXOGZEZZDKRR-UHFFFAOYSA-N COC1=CC2=C(NC(C(F)=C3)=CC=C3Cl)N=CN=C2C=C1OCC(C[S+]1CNCC1)O.Cl Chemical compound COC1=CC2=C(NC(C(F)=C3)=CC=C3Cl)N=CN=C2C=C1OCC(C[S+]1CNCC1)O.Cl AYHXOGZEZZDKRR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
VRXVUCLJIJWDMH-UHFFFAOYSA-N Cl.C1=CC=CC2=NC(OC)=NC=C21 Chemical compound Cl.C1=CC=CC2=NC(OC)=NC=C21 VRXVUCLJIJWDMH-UHFFFAOYSA-N 0.000 description 1
AOBYGTALIHMYNT-NSHDSACASA-N ClC1=CC(=C(C=C1)NC1=NC=NC2=CC(=C(C=C12)OC)OC[C@@H]1CO1)F Chemical compound ClC1=CC(=C(C=C1)NC1=NC=NC2=CC(=C(C=C12)OC)OC[C@@H]1CO1)F AOBYGTALIHMYNT-NSHDSACASA-N 0.000 description 1
AOBYGTALIHMYNT-LLVKDONJSA-N ClC1=CC(=C(C=C1)NC1=NC=NC2=CC(=C(C=C12)OC)OC[C@H]1CO1)F Chemical compound ClC1=CC(=C(C=C1)NC1=NC=NC2=CC(=C(C=C12)OC)OC[C@H]1CO1)F AOBYGTALIHMYNT-LLVKDONJSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
101150021185 FGF gene Proteins 0.000 description 1
101150009958 FLT4 gene Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
102100021866 Hepatocyte growth factor Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
AVOSNPGYXMDMDP-UHFFFAOYSA-N N-(4-bromo-2-fluorophenyl)-7-methoxyquinazolin-4-amine Chemical compound BrC1=CC(=C(C=C1)NC1=NC=NC2=CC(=CC=C12)OC)F AVOSNPGYXMDMDP-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000034038 Pathologic Neovascularization Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
FGUZXUFAUMIEMI-UHFFFAOYSA-N [1-(4-chloro-6-methoxyquinazolin-7-yl)oxy-3-piperidin-1-ylpropan-2-yl] acetate Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCC(OC(C)=O)CN1CCCCC1 FGUZXUFAUMIEMI-UHFFFAOYSA-N 0.000 description 1
SHKYVENKHLKXSX-UHFFFAOYSA-N [6-methoxy-7-(oxiran-2-ylmethoxy)-4-oxoquinazolin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound COC1=CC(C(N(COC(=O)C(C)(C)C)C=N2)=O)=C2C=C1OCC1CO1 SHKYVENKHLKXSX-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000003838 adenosines Chemical class 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
125000001118 alkylidene group Chemical group 0.000 description 1
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003432 anti-folate effect Effects 0.000 description 1
230000001740 anti-invasion Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940127074 antifolate Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
125000005163 aryl sulfanyl group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229960000997 bicalutamide Drugs 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000006243 carbonyl protecting group Chemical group 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000001721 carboxyacetyl group Chemical group 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000978 cyproterone acetate Drugs 0.000 description 1
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229950004203 droloxifene Drugs 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
229960001776 edrecolomab Drugs 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
229960004039 finasteride Drugs 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
150000005699 fluoropyrimidines Chemical class 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
229950002248 idoxifene Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000002485 inorganic esters Chemical class 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
150000002505 iron Chemical class 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
229950008959 marimastat Drugs 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
239000002609 medium Substances 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
QKYWADPCTHTJHQ-UHFFFAOYSA-N n,2-dimethylpropan-1-amine Chemical compound CNCC(C)C QKYWADPCTHTJHQ-UHFFFAOYSA-N 0.000 description 1
ZQGJEUVBUVKZKS-UHFFFAOYSA-N n,2-dimethylpropan-2-amine Chemical compound CNC(C)(C)C ZQGJEUVBUVKZKS-UHFFFAOYSA-N 0.000 description 1
CAJIOLKERBQYCQ-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-6-methoxy-7-phenylmethoxyquinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F CAJIOLKERBQYCQ-UHFFFAOYSA-N 0.000 description 1
JOHNIYZRJXDVBV-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-phenylmethoxyquinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F JOHNIYZRJXDVBV-UHFFFAOYSA-N 0.000 description 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
FNLUJDLKYOWMMF-UHFFFAOYSA-N n-ethyl-2-methylpropan-1-amine Chemical compound CCNCC(C)C FNLUJDLKYOWMMF-UHFFFAOYSA-N 0.000 description 1
RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
HQFYIDOMCULPIW-UHFFFAOYSA-N n-methylprop-2-yn-1-amine Chemical compound CNCC#C HQFYIDOMCULPIW-UHFFFAOYSA-N 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
229960002653 nilutamide Drugs 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
125000005633 phthalidyl group Chemical group 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229960004432 raltitrexed Drugs 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001210 retinal vessel Anatomy 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000012265 solid product Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
238000003419 tautomerization reaction Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
SFLXUZPXEWWQNH-UHFFFAOYSA-K tetrabutylazanium;tribromide Chemical compound [Br-].[Br-].[Br-].CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC SFLXUZPXEWWQNH-UHFFFAOYSA-K 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
229960005026 toremifene Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
238000001665 trituration Methods 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20024763A 2000-04-07 2002-10-03 Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav og farmasoytisk sammensetning NO324471B1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP00400967		2000-04-07
EP00400968		2000-04-07
EP00401034		2000-04-13
EP00401033		2000-04-13
PCT/GB2001/001514 WO2001077085A1 (en)	2000-04-07	2001-04-03	Quinazoline compounds

Publications (3)

Publication Number	Publication Date
NO20024763D0 NO20024763D0 (no)	2002-10-03
NO20024763L NO20024763L (no)	2002-11-19
NO324471B1 true NO324471B1 (no)	2007-10-29

Family

ID=27440054

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20024763A NO324471B1 (no)	2000-04-07	2002-10-03	Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav og farmasoytisk sammensetning

Country Status (20)

Country	Link
US (2)	US7160889B2 (de)
EP (1)	EP1274692B1 (de)
JP (2)	JP4970689B2 (de)
KR (1)	KR100858069B1 (de)
CN (1)	CN1240688C (de)
AT (1)	ATE334973T1 (de)
AU (1)	AU779695B2 (de)
BR (1)	BR0109828A (de)
CA (1)	CA2403365A1 (de)
CY (1)	CY1107539T1 (de)
DE (1)	DE60121931T2 (de)
DK (1)	DK1274692T3 (de)
ES (1)	ES2267748T3 (de)
IL (2)	IL151626A0 (de)
MX (1)	MXPA02009891A (de)
NO (1)	NO324471B1 (de)
NZ (1)	NZ521421A (de)
PT (1)	PT1274692E (de)
SI (1)	SI1274692T1 (de)
WO (1)	WO2001077085A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU90901A (sh)	1999-06-21	2004-07-15	Boehringer Ingelheim Pharma Gmbh. & Co.Kg.	Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje
CN100376567C (zh)	1999-11-05	2008-03-26	阿斯特拉曾尼卡有限公司	作为vegf抑制剂的喹唑啉衍生物
ATE300303T1 (de)	2000-03-06	2005-08-15	Astrazeneca Ab	Verwendung von quinazolinderivate als inhibitoren der angiogenese
UA73993C2 (uk)	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US7115615B2 (en)	2000-08-21	2006-10-03	Astrazeneca	Quinazoline derivatives
AU2001292138A1 (en)	2000-10-13	2002-04-22	Astrazeneca Ab	Quinazoline derivatives with anti-tumour activity
AU2001292137A1 (en)	2000-10-13	2002-04-22	Astrazeneca Ab	Quinazoline derivatives
AU2002217999A1 (en)	2000-11-01	2002-05-15	Cor Therapeutics, Inc.	Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US7019012B2 (en) *	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
WO2002085895A1 (en)	2001-04-19	2002-10-31	Astrazeneca Ab	Quinazoline derivatives
CN1625555A (zh)	2002-02-01	2005-06-08	阿斯特拉曾尼卡有限公司	喹唑啉化合物
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
ES2400339T3 (es)	2002-07-15	2013-04-09	Symphony Evolution, Inc.	Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
US7462623B2 (en)	2002-11-04	2008-12-09	Astrazeneca Ab	Quinazoline derivatives as Src tyrosine kinase inhibitors
AU2003292435A1 (en) *	2002-12-23	2004-07-14	Astrazeneca Ab	4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
US7223749B2 (en) *	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10326186A1 (de) *	2003-06-06	2004-12-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
GB0318423D0 (en) *	2003-08-06	2003-09-10	Astrazeneca Ab	Chemical compounds
DK1667991T3 (da)	2003-09-16	2008-08-18	Astrazeneca Ab	Quinazolinderivater som tyrosinkinaseinhibitorer
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
KR20060124646A (ko) *	2003-12-18	2006-12-05	씨브이 쎄러퓨틱스, 인코포레이티드	1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물
AU2005214373B2 (en) *	2004-02-19	2011-07-28	Rexahn Corporation	Quinazoline derivatives and therapeutic use thereof
AU2005223610B2 (en) *	2004-03-23	2008-05-29	Banyu Pharmaceutical Co., Ltd.	Substituted quinazoline or pyridopyrimidine derivative
AP2204A (en)	2004-05-06	2011-02-07	Warner Lambert Co	4-phenylamino-quinazolin-6-yl-amides.
AR050948A1 (es)	2004-09-24	2006-12-06	Hoffmann La Roche	Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US7285569B2 (en)	2004-09-24	2007-10-23	Hoff Hoffmann-La Roche Inc.	Tricycles, their manufacture and use as pharmaceutical agents
KR20070113286A (ko)	2005-04-14	2007-11-28	에프. 호프만-라 로슈 아게	아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
US7732613B2 (en)	2005-09-14	2010-06-08	Bristol-Myers Squibb Company	Met kinase inhibitors
EP1948179A1 (de)	2005-11-11	2008-07-30	Boehringer Ingelheim International GmbH	Chinazolin-derivate zur behandlung von krebserkrankungen
BRPI0717586A2 (pt) *	2006-09-18	2013-10-29	Boehringer Ingelheim Int	Método para tratar câncer apresentando mutações do egfr
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de)	2007-02-06	2008-08-14	Boehringer Ingelheim International Gmbh	Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US20080190689A1 (en) *	2007-02-12	2008-08-14	Ballard Ebbin C	Inserts for engine exhaust systems
US8497369B2 (en)	2008-02-07	2013-07-30	Boehringer Ingelheim International Gmbh	Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
NZ589883A (en)	2008-05-13	2012-06-29	Astrazeneca Ab	Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
EP2313397B1 (de)	2008-08-08	2016-04-20	Boehringer Ingelheim International GmbH	Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PL2451445T3 (pl)	2009-07-06	2019-09-30	Boehringer Ingelheim International Gmbh	Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
CN102060875B (zh) *	2009-11-18	2014-03-12	天津药物研究院	喹唑啉衍生物、制备方法和用途
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN105153047A (zh) *	2015-08-25	2015-12-16	佛山市赛维斯医药科技有限公司	含新型苯并喹唑啉和邻位氟结构的酪氨酸激酶抑制剂及用途
US20190112317A1 (en)	2015-10-05	2019-04-18	The Trustees Of Columbia University In The City Of New York	Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN106083836B (zh) *	2016-06-26	2021-08-20	徐州医学院	基于喹唑啉结构的h2s供体化合物及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE317376B (de)	1961-07-10	1969-11-17	Roussel Uclaf
US3266990A (en)	1963-09-24	1966-08-16	Warner Lambert Pharmaceutical	Derivatives of quinazoline
FR2077455A1 (en)	1969-09-03	1971-10-29	Aries Robert	5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3870725A (en)	1971-03-30	1975-03-11	Lilly Industries Ltd	Nitrothiazole derivatives
JPS542327A (en)	1977-06-07	1979-01-09	Sankyo Co Ltd	Agricultural and horticultural pesticide
JPS5538325A (en)	1978-09-11	1980-03-17	Sankyo Co Ltd	4-anilinoquinazoline derivative and its preparation
US4343940A (en)	1979-02-13	1982-08-10	Mead Johnson & Company	Anti-tumor quinazoline compounds
FR2498187A1 (fr)	1981-01-16	1982-07-23	Rhone Poulenc Sante	Procede de preparation d'amino-4 chloro-7 quinoleines
GB2160201B (en)	1984-06-14	1988-05-11	Wyeth John & Brother Ltd	Quinazoline and cinnoline derivatives
IL81307A0 (en)	1986-01-23	1987-08-31	Union Carbide Agricult	Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
EP0326307B1 (de)	1988-01-23	1994-08-17	Kyowa Hakko Kogyo Co., Ltd.	Pyridazinon-Derivate und diese enthaltende pharmazeutische Zubereitungen
US5411963A (en)	1988-01-29	1995-05-02	Dowelanco	Quinazoline derivatives
IL89029A (en)	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
HUT64755A (en)	1991-02-20	1994-02-28	Pfizer	Process for the production of 2,4-diamino-quinazoline derivatives and of medical preparatives containing them
IL101291A0 (en)	1991-03-22	1992-11-15	Nippon Soda Co	2-pyridine derivatives,their preparation and their use as fungicides
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en)	1991-05-10	1998-02-03	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
CA2102780C (en)	1991-05-10	2007-01-09	Alfred P. Spada	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JPH06504294A (ja)	1991-08-02	1994-05-19	ファイザー・インコーポレーテッド	免疫刺激剤としてのキノリン誘導体
GB9127252D0 (en)	1991-12-23	1992-02-19	Boots Co Plc	Therapeutic agents
GB9300059D0 (en)	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
DE4208254A1 (de)	1992-03-14	1993-09-16	Hoechst Ag	Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5270466A (en)	1992-06-11	1993-12-14	American Cyanamid Company	Substituted quinazoline fungicidal agents
JP2994165B2 (ja) *	1992-06-26	1999-12-27	ゼネカ・リミテッド	キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
US5712395A (en)	1992-11-13	1998-01-27	Yissum Research Development Corp.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en)	1992-11-13	1998-08-11	Sugen, Inc.	Quinazoline compounds and compositions thereof for the treatment of disease
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en)	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
GB9314893D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
US5656643A (en)	1993-11-08	1997-08-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
PL315941A1 (en)	1994-02-23	1996-12-09	Pfizer	4-heterocyclic substituted derivatives of quinazoline, methods of obtaining them and their application as anticarcinogenic agents
WO1995024190A2 (en)	1994-03-07	1995-09-14	Sugen, Inc.	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (de)	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en)	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
WO1996029331A1 (de)	1995-03-20	1996-09-26	Dr. Karl Thomae Gmbh	Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
IL117620A0 (en)	1995-03-27	1996-07-23	Fujisawa Pharmaceutical Co	Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
DE69536015D1 (de)	1995-03-30	2009-12-10	Pfizer Prod Inc	Chinazolinone Derivate
GB9508535D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508565D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
EP0824525B1 (de)	1995-04-27	2001-06-13	AstraZeneca AB	Chinazolin derivate
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508537D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
TW334434B (en)	1995-05-16	1998-06-21	Kanebo Ltd	Novel quinazoline compound and anti-tumor agent
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5773459A (en)	1995-06-07	1998-06-30	Sugen, Inc.	Urea- and thiourea-type compounds
US5650415A (en)	1995-06-07	1997-07-22	Sugen, Inc.	Quinoline compounds
DE69618587T2 (de)	1995-06-07	2002-08-29	Sugen, Inc.	Chinazoline und pharmazeutische zusammensetzungen
EP0836605B1 (de)	1995-07-06	2002-02-06	Novartis AG	Pyrolopyrimidine und verfahren zu ihrer herstellung
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
WO1997017329A1 (en)	1995-11-07	1997-05-15	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
WO1997030035A1 (en) *	1996-02-13	1997-08-21	Zeneca Limited	Quinazoline derivatives as vegf inhibitors
GB9603097D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
ES2169355T3 (es) *	1996-03-05	2002-07-01	Astrazeneca Ab	Derivados de 4-anilinoquinazolina.
JP2000506880A (ja)	1996-03-15	2000-06-06	ゼネカ・リミテッド	シンノリン誘導体及びその使用
AU5533996A (en)	1996-04-04	1997-10-29	University Of Nebraska Board Of Regents	Synthetic triple helix-forming compounds
JP3370340B2 (ja) *	1996-04-12	2003-01-27	ワーナー―ランバート・コンパニー	チロシンキナーゼの不可逆的阻害剤
GB9607729D0 (en)	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
DE19614718A1 (de)	1996-04-15	1997-10-16	Hoechst Schering Agrevo Gmbh	Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
GB9613021D0 (en)	1996-06-21	1996-08-28	Pharmacia Spa	Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
DE69716916T2 (de)	1996-07-13	2003-07-03	Glaxo Group Ltd., Greenford	Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
AU4342997A (en)	1996-09-13	1998-04-02	Sugen, Inc.	Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
AU733551B2 (en)	1996-09-25	2001-05-17	Astrazeneca Ab	Qinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
CA2239227C (en)	1996-10-01	2007-10-30	Kyowa Hakko Kirin Co., Ltd.	Nitrogen-containing heterocyclic compounds
EP0837063A1 (de)	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazolinderivate
CA2272705C (en)	1996-11-27	2003-03-18	Pfizer Inc.	Fused bicyclic pyrimidine derivatives
CO4950519A1 (es)	1997-02-13	2000-09-01	Novartis Ag	Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US5929080A (en)	1997-05-06	1999-07-27	American Cyanamid Company	Method of treating polycystic kidney disease
ES2201484T3 (es)	1997-05-06	2004-03-16	Wyeth Holdings Corporation	Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal.
ZA986729B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
AR016817A1 (es)	1997-08-14	2001-08-01	Smithkline Beecham Plc	Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
ATE368665T1 (de)	1997-08-22	2007-08-15	Astrazeneca Ab	Oxindolylchinazolinderivate als angiogenesehemmer
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
EP1119567B1 (de)	1998-10-08	2005-05-04	AstraZeneca AB	Chinazolin derivate
BRPI0017548B8 (pt)	1999-02-10	2023-05-02	Astrazeneca Ab	Composto
DE19911509A1 (de)	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN100376567C (zh)	1999-11-05	2008-03-26	阿斯特拉曾尼卡有限公司	作为vegf抑制剂的喹唑啉衍生物
ATE300303T1 (de)	2000-03-06	2005-08-15	Astrazeneca Ab	Verwendung von quinazolinderivate als inhibitoren der angiogenese
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
CA2416525A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Indole, azaindole and indazole derivatives having vegf inhibiting activity
CN1315822C (zh)	2000-08-09	2007-05-16	阿斯特拉曾尼卡有限公司	具有vegf抑制活性的喹啉衍生物
AU2001276521B2 (en)	2000-08-09	2006-05-25	Astrazeneca Ab	Cinnoline compounds
GB0126879D0 (en)	2001-11-08	2002-01-02	Astrazeneca Ab	Combination therapy
CN1625555A (zh)	2002-02-01	2005-06-08	阿斯特拉曾尼卡有限公司	喹唑啉化合物
GB0218526D0 (en)	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
US20050222183A1 (en)	2002-08-09	2005-10-06	Wedge Stephen R	Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en)	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
DK1592423T3 (da)	2003-02-13	2011-06-27	Astrazeneca Ab	Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11

2001
- 2001-04-03 US US10/240,658 patent/US7160889B2/en not_active Expired - Fee Related
- 2001-04-03 EP EP01921530A patent/EP1274692B1/de not_active Expired - Lifetime
- 2001-04-03 DK DK01921530T patent/DK1274692T3/da active
- 2001-04-03 ES ES01921530T patent/ES2267748T3/es not_active Expired - Lifetime
- 2001-04-03 NZ NZ521421A patent/NZ521421A/en unknown
- 2001-04-03 IL IL15162601A patent/IL151626A0/xx active IP Right Grant
- 2001-04-03 AU AU48507/01A patent/AU779695B2/en not_active Ceased
- 2001-04-03 BR BR0109828-4A patent/BR0109828A/pt not_active IP Right Cessation
- 2001-04-03 DE DE60121931T patent/DE60121931T2/de not_active Expired - Lifetime
- 2001-04-03 KR KR1020027013364A patent/KR100858069B1/ko not_active Expired - Fee Related
- 2001-04-03 SI SI200130631T patent/SI1274692T1/sl unknown
- 2001-04-03 JP JP2001575560A patent/JP4970689B2/ja not_active Expired - Fee Related
- 2001-04-03 CN CNB018106846A patent/CN1240688C/zh not_active Expired - Fee Related
- 2001-04-03 WO PCT/GB2001/001514 patent/WO2001077085A1/en not_active Ceased
- 2001-04-03 PT PT01921530T patent/PT1274692E/pt unknown
- 2001-04-03 MX MXPA02009891A patent/MXPA02009891A/es active IP Right Grant
- 2001-04-03 CA CA002403365A patent/CA2403365A1/en not_active Abandoned
- 2001-04-03 AT AT01921530T patent/ATE334973T1/de not_active IP Right Cessation
2002
- 2002-09-05 IL IL151626A patent/IL151626A/en not_active IP Right Cessation
- 2002-10-03 NO NO20024763A patent/NO324471B1/no not_active IP Right Cessation
2006
- 2006-11-01 CY CY20061101562T patent/CY1107539T1/el unknown
- 2006-11-17 US US11/600,752 patent/US20070066633A1/en not_active Abandoned
2012
- 2012-02-23 JP JP2012037026A patent/JP2012136537A/ja active Pending

Also Published As

Publication number	Publication date
IL151626A0 (en)	2003-04-10
AU779695B2 (en)	2005-02-10
PT1274692E (pt)	2006-11-30
IL151626A (en)	2008-06-05
SI1274692T1 (sl)	2006-12-31
US20070066633A1 (en)	2007-03-22
WO2001077085A1 (en)	2001-10-18
ES2267748T3 (es)	2007-03-16
JP2012136537A (ja)	2012-07-19
DE60121931D1 (de)	2006-09-14
NO20024763L (no)	2002-11-19
EP1274692A1 (de)	2003-01-15
JP2003530387A (ja)	2003-10-14
DE60121931T2 (de)	2007-03-01
CY1107539T1 (el)	2013-03-13
NO20024763D0 (no)	2002-10-03
CA2403365A1 (en)	2001-10-18
EP1274692B1 (de)	2006-08-02
CN1240688C (zh)	2006-02-08
DK1274692T3 (da)	2006-10-30
JP4970689B2 (ja)	2012-07-11
ATE334973T1 (de)	2006-08-15
MXPA02009891A (es)	2003-03-27
KR20020084295A (ko)	2002-11-04
CN1433405A (zh)	2003-07-30
AU4850701A (en)	2001-10-23
US20030191308A1 (en)	2003-10-09
US7160889B2 (en)	2007-01-09
NZ521421A (en)	2004-09-24
KR100858069B1 (ko)	2008-09-22
BR0109828A (pt)	2002-12-17

Legal Events

Date	Code	Title	Description
2010-11-29	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
AU779695B2 (en)	2005-02-10	Quinazoline compounds
CA2362715C (en)	2010-10-19	Quinazoline derivatives as angiogenesis inhibitors
EP1005470B1 (de)	2007-08-01	Oxindolylchinazolinderivate als angiogenesehemmer
EP1309587B1 (de)	2008-12-31	Cinnoline verbindungen
US20070265286A1 (en)	2007-11-15	Quinazoline derivatives as VEGF inhibitors
US20030225111A1 (en)	2003-12-04	Therapy
US20030199491A1 (en)	2003-10-23	Quinoline derivatives having vegf inhibiting activity
WO2002016348A1 (en)	2002-02-28	Antiangiogenic bicyclic derivatives
NO328731B1 (no)	2010-05-03	Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk preparat.
PT873319E (pt)	2002-01-30	Derivados de quinazolina
KR20000048572A (ko)	2000-07-25	퀴나졸린 유도체 및 이를 포함하는 약학적 조성물
US20030207878A1 (en)	2003-11-06	Chemical compounds
AU2001276536A1 (en)	2002-05-16	Quinoline derivatives having vegf inhibiting activity
AU2004263360A1 (en)	2005-02-17	Quinazoline derivatives as angiogenesis inhibitors
MXPA06001394A (es)	2006-05-19	Derivados de quinazolina como inhibidores de cinasas de tirosina de receptor vegf.